Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial

Crohn's Disease Clinical Trial

Official title:

Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02256462
• Other study ID #: PAILOT
• Status: Completed
• Phase: Phase 4
• Start date: May 1, 2015
• Est. completion date: January 31, 2019

Study information

• Verified date: September 2021
• Source: Schneider Children's Medical Center, Israel
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Objectives: To examine the effect of drug level-based personalized treatment of adalimumab in children with Crohn's disease. Design: A prospective, randomized, open label study. Setting: Pediatric gastroenterology centers. Participants: Children 6 year to 17 years who are diagnosed with CD and are planned to receive adalimumab treatment. Main outcome measures: Pediatric Crohn's Activity Index (PCDAI) at 48 and 72 weeks. Secondary outcome measures: Corticosteroids free remission rates and on adalimumab at 48 and 72 weeks. The effect of routine adalimumab drug monitoring-based treatment on trough levels and anti-adalimumab antibodies during therapy.

Description:

The efficacy of adalimumab in inducing and maintaining remission in both adults and children with moderate-to-severe Crohn's Disease has been demonstrated in multiple clinical trials. Despite efforts to optimize treatment, approximately 40% of patients who initially respond to anti-TNF ultimately lose response. Measurement of adalimumab (ADA) drug levels and antibodies to adalimumab (ATAs) in patients has been shown to assist decision making in patients who have lost response during the course of treatment. This approach is based on the observations showing that higher ADA concentrations are associated with higher treatment efficacy and that loss of response is primarily attributed to either undetectable drug levels or to the presence of high titers of ATAs. Existing data is mostly based on retrospective cohort studies, nevertheless, the concept of routine therapeutic drug monitoring in-order to improve efficacy is still evolving. Recently, preliminary results of the Trough level Adapted infliXImab Treatment (TAXIT) study, performed in adult IBD patients, have failed to demonstrate superiority of level-based treatment over clinically-based treatment regarding rates of response over time. Nevertheless, it is premature to conclude that patients do not benefit from a tailored approach as the reported abstract did not stratify patients according to type of disease (CD vs. ulcerative colitis) and as some significant advantages such as reduced rate of antibodies and reduction of CRP were described in the level-based arm. Anti-TNF treatment in pediatric patients may differ from adults due to a higher risk for developing the rare hepatosplenic T cell lymphomas (HSCTL) in young males treated with combination therapy including thiopurines and anti-TNF agents. Concomitant therapy (using immunomodulators, mainly azathioprine) which has demonstrated superiority over mono-therapy has become a standard of care in moderate to severe CD in adults. In-view of the concerns of pediatric gastroenterologist from concomitant therapy-induced adverse events the option to improve efficacy of mono-therapy by guiding it according to drug monitoring is further appealing. Therefore, our aim is to assess the efficacy of routine therapeutic drug monitoring based treatment in pediatric CD patients in a prospective randomized control trial. We hope that this study will further contribute to the understanding of the potential benefits of therapeutic drug monitoring based management in pediatric patients treated with anti-TNF agents.Hypothesis:

We hypothesize that by routine measuring of ADA trough levels and ATAs titers we will achieve higher and stable trough levels resulting in greater corticosteroid free remission rates and decreased LOR rates. We assume that this will be associated with lower frequencies of ATAs. We further assume that the intervention will reduce the need for alteration of treatment schemes by adding immunomodulators or by switching treatment within class or out of class.

Objectives:

This is ADA therapy optimization study in patients starting or receiving ADA due to active disease.

1. Primary Efficacy Objective: To evaluate the effect of routine ADA drug monitoring-based treatment, in comparison to clinically-based monitoring on disease activity.

2. Secondary Objective: To evaluate the effect of routine ADA drug monitoring-based treatment on trough levels and ATAs during therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 82
• Est. completion date: January 31, 2019
• Est. primary completion date: January 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 17 Years

Eligibility

Inclusion Criteria:

1. Crohn's disease

2. Age 6-17 (inclusive)

3. Naïve to biologics

4. Informed consent

5. Neg. TB-Test, negative HBV- S Ag

6. Negative stool culture, parasites and clostridium toxin

Inclusion criteria Comments:

1. Patients receiving corticosteroids may be included if on taper-down scheduled to be completed by week 10.

2. Partial enteral nutrition, accounting for less than 50% of daily required calories, may be supplied as needed.

3. Patients receiving antibiotics must cease use of antibiotics within the 14 days of receiving the first injection. Excluding immunomodulators (azathioprine/6MP and methotrexate), any other targeted therapy for crohn's disease (i.e 5-ASA) must be stopped prior to ADA first injection. Immunomodulators will be required to be stopped either prior to first ADA injection or at 6 months following ADA initiation.

Exclusion Criteria:

1. Pregnancy.

2. Renal Failure.

3. Current abscess or perforation of the bowel.

4. Small bowel obstruction within the last 6 months.

5. Fixed non inflammatory stricture with related symptoms.

6. Complicated or heavily draining perianal fistula (indolent non draining or minimally draining fistula are not an exclusion criteria).

7. Prior treatment with infliximab or adalimumab.

8. Previous malignancy.

9. Sepsis or active bacterial infection.

10. Surgery related to Crohn's disease in the previous 8 weeks.

11. Positive Hepatitis B surface antigen or evidence for TB.

12. IBD unclassified.

Related Conditions & MeSH terms

• Crohn Disease
• Crohn's Disease

Intervention

Drug:
• Adalimumab
Eligible patients are those who are planned to start Adalimumab (ADA). Patients will be randomized at the first screening visits to either group 1 (interventional) or group 2 (clinical). Eligible patients, will start induction treatment (weeks 0,2) with ADA (> 40kg 160/80/40 mg every 2 weeks or < 40 kg 100/50/25 mg for m2 body surface area every 2 weeks). Interventions will start from the 4th injection for responding patients only (based on levels taken prior to the third injection). Responding patients will continue to the maintenance phase in which they will receive ADA every 2 weeks, either 40 mg or 25 mg/m2. At screening, and every 2 months all patients will be examined and have height, weight, PCDAI performed as well as comprehensive laboratory examinations.

Locations

Country	Name	City	State
Israel	Schneider Children's Hospital	Petach Tikva

Sponsors (1)

Lead Sponsor	Collaborator
Schneider Children's Medical Center, Israel

Country where clinical trial is conducted

Israel, 

References & Publications (4)

Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007 Jan;132(1):52-65. Epub 2006 Nov 29. — View Citation

Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006 Feb;130(2):323-33; quiz 591. — View Citation

Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009 Nov;137(5):1628-40. doi: 10.1053/j.gastro.2009.07.062. Epub 2009 Aug 5. — View Citation

Paul S, Moreau AC, Del Tedesco E, Rinaudo M, Phelip JM, Genin C, Peyrin-Biroulet L, Roblin X. Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014 Jul;20(7):1288-95. doi: 10.1097/MIB.0000000000000037. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Loss of response (LOR) during treatment.	Patients with loss of response are defined as those with a good initial clinical response to anti-TNFa, with a later clinical and biochemical relapse defined as PCDAI=10 (for patients in remission) or an increase of 15 points PCDAI from post induction baseline and CRP> 0.5mg/dl and/or calprotectin>150µgr/gr	Week 72
Secondary	Corticosteroids free complete clinical remission, on ADA,	Patients with PCDAI<10, and quiescent disease by physician global assessment (PGA).	48 and 72 weeks
Secondary	Trough levels	Mean adalimumab trough levels	8, 16, 32, 48, 72 weeks
Secondary	Antibodies to adalimumab	Presence of antibodies to adalimumab (ATAs)	8, 16, 32, 48, 72 weeks
Secondary	Anthropometric indices	Anthropometric indices (weight, height, BMI) and growth assessment during scheduled visits	0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, weeks
Secondary	Laboratory markers	Laboratory surrogate markers (CBC, ESR, CRP, albumin, fecal calprotectin) during scheduled visits	0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, weeks
Secondary	Adverse events	Medication associated adverse events	4, 8, 16, 24, 32, 40, 48, 56, 64, 72, weeks
Secondary	The need for treatment modification during therapy	Addition of immunomodulator, switch within/out of class	Week 72
Secondary	Disease activity defined by PCDAI	Pediatric Crohn's Disease Activity Index	48 and 72 weeks